TaVec400 treatment for difficult-to-treat autoimmune diseases
Part of Brain & nervous system, Immune system & allergy, Skin clinical trials.
This early-stage study tests whether a new treatment called LVIVO-TaVec400 can help patients whose autoimmune diseases (like lupus, multiple sclerosis, myasthenia gravis, or IgG4-related disease) have not responded well to standard treatments. The goal is to see if this approach can reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–65 years old
- You have one of four specific autoimmune conditions: lupus (SLE), IgG4-related disease, progressive multiple sclerosis, or myasthenia gravis
- Your condition has not improved adequately with current treatments or has come back despite treatment
- You have adequate organ function (healthy kidneys, liver, heart) based on blood tests
- You do not have active infections like hepatitis or tuberculosis
- You are not pregnant, breastfeeding, or planning to become pregnant during the study and for 1 year after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of immune cell therapy (LVIVO-TaVec122) designed to fight back against B-cell lymphomas and leukemias that have stopped responding to previous treatments. The goal is to see if this therapy is safe and how well it works.
This early-phase trial tests an experimental treatment called LUCAR-DKS1, which uses your own immune cells to target and control severe autoimmune diseases like lupus, vasculitis, and scleroderma that haven't responded to other treatments.
This trial tests a new gene therapy, LVIVO-TaVec400, for people with multiple myeloma that has come back or not responded to treatment. The goal is to see if it can help when other treatments have stopped working.
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Hear when a new Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.